LIVIVO - Search results -

Search results

Result 1 - 10 of total 931

Search options

Article ; Online: Awareness and education in lung diseases: Are we reaching the target?

Gomes, Ricardo Estêvão / Saraiva, Isabel / Morais-Almeida, Mário

2022 Volume 28, Issue 5, Page(s) 330–332

MeSH term(s)	Humans ; Lung Diseases ; Pulmonary Disease, Chronic Obstructive
Language	English
Publishing date	2022-05-09
Publishing country	Spain
Document type	Journal Article
ZDB-ID	3009651-0
ISSN	2531-0437 ; 2531-0429
ISSN (online)	2531-0437
ISSN	2531-0429
DOI	10.1016/j.pulmoe.2022.02.011
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Article ; Online: Biological therapies, asthma and coronavirus disease 2019.

Ribeiro, Amélia / Aguiar, Rita / Morais-Almeida, Mário

Current opinion in allergy and clinical immunology

2021 Volume 21, Issue 6, Page(s) 597–601

Abstract: Purpose of review: As of June 2021, coronavirus disease 2019 (COVID-19) exceeded 180 million reported cases and was responsible for almost 4 million deaths globally. Asthma affects approximately 262 million people worldwide and is an important cause of ... ...

Abstract	Purpose of review: As of June 2021, coronavirus disease 2019 (COVID-19) exceeded 180 million reported cases and was responsible for almost 4 million deaths globally. Asthma affects approximately 262 million people worldwide and is an important cause of morbidity and mortality. Presently, it appears asthma is neither associated with an increased risk of contracting COVID-19 nor with a risk of severe COVID-19 or COVID-19 related death. Regarding the severe asthma patients on biologics, questions remain. The purpose of this review is to discuss the evidence regarding the relationship between asthma, biologics and COVID-19. Recent findings: The available evidence does not suggest that severe asthmatics on treatment with biologics have a higher risk of severe acute respiratory syndrome coronavirus 2 infection compared to the general population. It does not appear that they have a higher risk of severe disease or COVID-19 related death either. Summary: This review suggests that treatment with biologics for severe asthma is safe and should be maintained during the COVID-19 pandemic. However, more studies are needed to address this question and the role of biological therapy on different asthma phenotypes.
MeSH term(s)	Asthma/diagnosis ; Asthma/drug therapy ; Asthma/immunology ; Biological Products/administration & dosage ; Biological Products/adverse effects ; COVID-19/diagnosis ; COVID-19/immunology ; COVID-19/mortality ; Humans ; Immunologic Factors/administration & dosage ; Immunologic Factors/adverse effects ; Risk Assessment/statistics & numerical data ; Risk Factors ; SARS-CoV-2/immunology ; Severity of Illness Index
Chemical Substances	Biological Products ; Immunologic Factors
Language	English
Publishing date	2021-09-20
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2088710-3
ISSN	1473-6322 ; 1528-4050
ISSN (online)	1473-6322
ISSN	1528-4050
DOI	10.1097/ACI.0000000000000783
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5666: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Asthma and pregnancy in the 2020 decade: still a matter of concern.

Vieira, Ana Cláudia / Pité, Helena / Morais-Almeida, Mário

The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians

2021 Volume 35, Issue 25, Page(s) 6498–6504

Abstract: Asthma is a fairly common health problem for pregnant women and a potentially serious medical condition that may complicate pregnancy. Most complications are related to lack of disease control, which can adversely affect both maternal quality of life and ...

Abstract	Asthma is a fairly common health problem for pregnant women and a potentially serious medical condition that may complicate pregnancy. Most complications are related to lack of disease control, which can adversely affect both maternal quality of life and perinatal outcomes. In this article, we review recent literature concerning asthma in pregnancy, describing the course of the disease and associated complications. Furthermore, we review and discuss asthma monitoring and management during pregnancy, labor and post-partum. The course of asthma symptoms during pregnancy is unpredictable but exacerbations are more common during the second trimester. The causes are multifactorial and asthma phenotype may have a role. It has been proposed that combined use of CARAT (Control of Allergic Rhinitis and Asthma Test) and lung function tests can be used to monitor and adjust therapy during pregnancy in patients with asthma. As a complement, an approach that considers airway inflammation assessment using fractional exhaled nitric oxide (FeNO), a noninvasive marker of inflammation, may improve asthma control during pregnancy. It is important to consider a few but relevant differences in asthma management and treatment regarding pregnancy and the peri-partum period to safely achieve optimal management of asthma during all these phases for both mother and offsprings.
MeSH term(s)	Female ; Pregnancy ; Humans ; Breath Tests ; Quality of Life ; Nitric Oxide ; Asthma/diagnosis ; Asthma/epidemiology ; Asthma/therapy ; Inflammation
Chemical Substances	Nitric Oxide (31C4KY9ESH)
Language	English
Publishing date	2021-04-29
Publishing country	England
Document type	Review ; Journal Article
ZDB-ID	2077261-0
ISSN	1476-4954 ; 1057-0802 ; 1476-7058
ISSN (online)	1476-4954
ISSN	1057-0802 ; 1476-7058
DOI	10.1080/14767058.2021.1916462
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 3510: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The reality of LAMAs for adult asthmatic patients.

Luz, Maria Inês / Aguiar, Rita / Morais-Almeida, Mário

Expert review of respiratory medicine

2020 Volume 14, Issue 11, Page(s) 1087–1094

Abstract: Introduction: The use of tiotropium is approved for the treatment of asthma. There are several studies completed or currently ongoing with the long-acting muscarinic antagonists (LAMAs) umeclidinium and glycopyrronium as an add-on asthma treatment. ... ...

Abstract	Introduction: The use of tiotropium is approved for the treatment of asthma. There are several studies completed or currently ongoing with the long-acting muscarinic antagonists (LAMAs) umeclidinium and glycopyrronium as an add-on asthma treatment. Adding a second bronchodilator with a different mechanism of action for the treatment of uncontrolled asthma may be a suitable therapeutic approach, although several issues still under discussion. Areas covered: The reality of LAMA plus long-acting beta-agonists (LABA) treatment for adult asthma. A systematic search was conducted on March 2020, and included 6 electronic databases: EMBASE, MEDLINE, Scopus, The Cochrane Library, Web of Science and Google Scholar. Expert opinion: A growing body of evidence generated from several randomized clinical trials is supporting the use of LAMA in adulthood asthma always in association with inhaled corticosteroid (ICS). Currently, only tiotropium has been approved and included in the guidelines. Other LAMAs are under evaluation in clinical trials. Several clinical trials are supporting the use of a triple therapy (ICS/LABA/LAMA) in uncontrolled asthmatic patients under ICS/LABA.
MeSH term(s)	Administration, Inhalation ; Adrenal Cortex Hormones/therapeutic use ; Adult ; Age of Onset ; Asthma/drug therapy ; Asthma/epidemiology ; Bronchodilator Agents/therapeutic use ; Delayed-Action Preparations ; Drug Therapy, Combination ; Humans ; Muscarinic Antagonists/therapeutic use ; Quinuclidines/therapeutic use ; Tiotropium Bromide/therapeutic use
Chemical Substances	Adrenal Cortex Hormones ; Bronchodilator Agents ; Delayed-Action Preparations ; Muscarinic Antagonists ; Quinuclidines ; Tiotropium Bromide (XX112XZP0J)
Language	English
Publishing date	2020-07-20
Publishing country	England
Document type	Journal Article ; Systematic Review
ZDB-ID	2479146-5
ISSN	1747-6356 ; 1747-6348
ISSN (online)	1747-6356
ISSN	1747-6348
DOI	10.1080/17476348.2020.1794828
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 6963: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Asthma Across Childhood: Improving Adherence to Asthma Management from Early Childhood to Adolescence.

Rehman, Narmeen / Morais-Almeida, Mário / Wu, Ann Chen

The journal of allergy and clinical immunology. In practice

2020 Volume 8, Issue 6, Page(s) 1802–1807.e1

Abstract: Asthma affects nearly 6 million US children. Throughout childhood, children undergo a series of biological, developmental, and psychosocial changes. Thus, factors influencing a child's asthma management differ across 3 essential stages-early childhood (0- ...

Abstract	Asthma affects nearly 6 million US children. Throughout childhood, children undergo a series of biological, developmental, and psychosocial changes. Thus, factors influencing a child's asthma management differ across 3 essential stages-early childhood (0-5 years), school-aged years (5-12 years), and adolescence (12-18 years)-and require varied intervention by parents, school personnel, clinicians, and the children themselves. Because asthma care in children is characterized by fluctuations in severity and coordination among many stakeholders, optimal asthma control is difficult to achieve in this young population. Challenges in childhood asthma management are reflected in the low rates of children's adherence to medication regimes. Although pharmacological and biological factors addressing age in physicians' treatment choices are well outlined, age-specific approaches to patient-provider communication and asthma-related interventions are also important in improving quality of life for patients with pediatric asthma.
MeSH term(s)	Adolescent ; Asthma/drug therapy ; Asthma/epidemiology ; Child ; Child, Preschool ; Communication ; Humans ; Parents ; Quality of Life ; Schools
Language	English
Publishing date	2020-02-26
Publishing country	United States
Document type	Journal Article ; Research Support, N.I.H., Extramural
ZDB-ID	2843237-X
ISSN	2213-2201 ; 2213-2198
ISSN (online)	2213-2201
ISSN	2213-2198
DOI	10.1016/j.jaip.2020.02.011
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 7086: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: The challenges and facilitators of self-management in pediatric asthma.

Pité, Helena / Carvalho, Sara / Morais-Almeida, Mário

Current opinion in allergy and clinical immunology

2020 Volume 21, Issue 2, Page(s) 135–143

Abstract: Purpose of review: Self-management education in asthma can dramatically reduce asthma morbidity, but specific pediatric challenges need to be addressed. The purpose of this review is to discuss the most recent and significant advances regarding self- ... ...

Abstract	Purpose of review: Self-management education in asthma can dramatically reduce asthma morbidity, but specific pediatric challenges need to be addressed. The purpose of this review is to discuss the most recent and significant advances regarding self-management interventions in pediatric asthma. Recent findings: Recent evidence supports school-based programs including asthma self-management skills for children to significantly improve asthma control. A defined theoretical intervention framework, parent involvement, child satisfaction, and running the intervention outside the child's own free time are suggested drivers of successful implementation. Real-time telemedically delivered asthma education may also improve asthma-related outcomes in children. Moreover, mobile applications supporting self-management are generally welcomed by children and parents. Current evidence supports the use of models of health behaviors change in mobile application design and content development; self-monitoring alone is ineffective but useful when coupled with decision support for proactive care. Summary: School-based and e-health interventions are potential facilitators for the implementation of successful self-management asthma programs, providing access to large numbers of children with asthma. This supports the healthcare practitioners to work together with researchers to promote these interventions, while following current recommendations for the effective transition of children into competent and confident adults to continue to successfully self-manage their asthma.
MeSH term(s)	Adult ; Asthma/therapy ; Child ; Family ; Humans ; Parents ; Schools ; Self-Management
Language	English
Publishing date	2020-11-26
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2088710-3
ISSN	1473-6322 ; 1528-4050
ISSN (online)	1473-6322
ISSN	1528-4050
DOI	10.1097/ACI.0000000000000731
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5666: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article: Prevalence, Presentation and Outcomes of Silent Hypoxemia in COVID-19.

Ribeiro, Amélia / Mendonça, Mauro / Sabina Sousa, Cláudia / Trigueiro Barbosa, Miguel / Morais-Almeida, Mário

Clinical medicine insights. Circulatory, respiratory and pulmonary medicine

2022 Volume 16, Page(s) 11795484221082761

Abstract: Dyspnea is reported in a minority of patients affected by coronavirus disease 2019 (COVID-19). Even patients with pneumonia can present hypoxemia without any respiratory distress, a phenomenon known as "silent" or "happy hypoxemia". During the current ... ...

Abstract	Dyspnea is reported in a minority of patients affected by coronavirus disease 2019 (COVID-19). Even patients with pneumonia can present hypoxemia without any respiratory distress, a phenomenon known as "silent" or "happy hypoxemia". During the current pandemic there were only a few studies conducted on this subject and these were quite heterogeneous. Therefore, the prevalence of "silent hypoxemia" varied substantially. While studies did not show a clear tendency of "silent hypoxemia" to poorer outcomes compared to hypoxemia presenting with dyspnea, several showed that patients with "silent hypoxemia" are not protected from poor outcomes either. There is a need for a uniform definition of "silent hypoxemia", in order to better guide clinicians and investigators. More studies are needed to shed light on the mechanisms of "silent hypoxemia", as well as its presentation and influence in the disease's progression and outcomes, so as to better assist physicians in the care of COVID-19 patients.
Language	English
Publishing date	2022-02-23
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2583465-4
ISSN	1179-5484
ISSN	1179-5484
DOI	10.1177/11795484221082761
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Economic burden of drug-induced anaphylaxis: what can we do better?

Cardoso, Barbara / Moscoso, Teresa / Morais-Almeida, Mário / Demoly, Pascal / Tanno, Luciana K

Current opinion in allergy and clinical immunology

2022 Volume 22, Issue 4, Page(s) 234–241

Abstract: Purpose of review: This systematic review evaluates published data related to the economic burden of drug-induced anaphylaxis (DIA) to understand preventive cost saving measures that could reduce the burden of these conditions.: Recent findings: ... ...

Abstract	Purpose of review: This systematic review evaluates published data related to the economic burden of drug-induced anaphylaxis (DIA) to understand preventive cost saving measures that could reduce the burden of these conditions. Recent findings: Although DIA has a relevant societal impact, there are limited and heterogenous available data related to its cost. Direct costs related to the management of acute phase of DIA was estimated by $529.6 to $3125, depending on the number of emergency room visits/hospitalizations, emergency kits and transports in ambulance. Direct costs of investigations of DIA varied from $288 to $2292.95 and the desensitization was estimated by $6796. Main variables for this were: personnel, allergy screening procedures, medical consumables and space cost. The mean indirect cost was based on a mean absenteeism of 3 days per DIA corresponding to $381.2. Summary: More than reviewing the published data, we were able to identify variables that, if correctly managed, can reduce the economic burden of DIA, such as adjusting the timing of referral and etiological diagnosis, identification of potential risk and/or co-factors, correct written recommendations to patients. The evidence presented highlights the need of optimization of healthcare patients to patients suffering from DIA.
MeSH term(s)	Absenteeism ; Anaphylaxis/diagnosis ; Anaphylaxis/epidemiology ; Anaphylaxis/prevention & control ; Cost of Illness ; Drug Hypersensitivity ; Financial Stress ; Health Care Costs ; Humans
Language	English
Publishing date	2022-07-18
Publishing country	United States
Document type	Journal Article ; Systematic Review ; Research Support, Non-U.S. Gov't
ZDB-ID	2088710-3
ISSN	1473-6322 ; 1528-4050
ISSN (online)	1473-6322
ISSN	1528-4050
DOI	10.1097/ACI.0000000000000836
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5666: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Spirometry Outside the Hospital.

Morais-Almeida, Mário / Barbosa, Miguel T / Sousa, Cláudia S / Almeida, Isabel / Pimenta, Lara / Aguiar, Rita

Archivos de bronconeumologia

2021 Volume 57, Issue 3, Page(s) 236

MeSH term(s)	Hospitals ; Spirometry
Language	English
Publishing date	2021-03-10
Document type	Letter ; Comment
ZDB-ID	733126-5
ISSN	1579-2129 ; 0300-2896
ISSN (online)	1579-2129
ISSN	0300-2896
DOI	10.1016/j.arbr.2020.10.011
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2655: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The first impression counts for lung function: One year to make a difference in asthma prognosis.

Pite, Helena / Sanchez-Garcia, Silvia / Morais-Almeida, Mário

Allergy

2019 Volume 75, Issue 1, Page(s) 12–13

MeSH term(s)	Asthma ; Forced Expiratory Volume ; Humans ; Prognosis ; Prospective Studies
Language	English
Publishing date	2019-08-24
Publishing country	Denmark
Document type	Editorial ; Comment
ZDB-ID	391933-x
ISSN	1398-9995 ; 0105-4538
ISSN (online)	1398-9995
ISSN	0105-4538
DOI	10.1111/all.14025
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Uh III Zs.150: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 125: Show issues

Order via subito

Details ▾

To top

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito